Molecular markers predictive response to dose dense chemotherapy with epirubicin and docetaxel in sequences for locally advanced breast cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Epirubicin; Pegfilgrastim
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms MEDOBREC
- 22 Mar 2021 Biomarkers information updated
- 16 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Jul 2007 New trial record.